Advantages and pitfalls in fluid biomarkers for diagnosis of Alzheimer’s disease

Syed Haris Omar, John Preddy

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)
27 Downloads (Pure)


Alzheimer’s disease (AD) is a commonly occurring neurodegenerative disease in the advanced-age population, with a doubling of prevalence for each 5 years of age above 60 years. In the past two decades, there has been a sustained effort to find suitable biomarkers that may not only aide with the diagnosis of AD early in the disease process but also predict the onset of the disease in asymptomatic individuals. Current diagnostic evidence is supportive of some biomarker candidates isolated from cerebrospinal fluid (CSF), including amyloid beta peptide (Aβ), total tau (t-tau), and phosphorylated tau (p-tau) as being involved in the pathophysiology of AD. However, there are a few biomarkers that have been shown to be helpful, such as proteomic, inflammatory, oral, ocular and olfactory in the early detection of AD, especially in the individuals with mild cognitive impairment (MCI). To date, biomarkers are collected through invasive techniques, especially CSF from lumbar puncture; however, non-invasive (radio imaging) methods are used in practice to diagnose AD. In order to reduce invasive testing on the patients, present literature has highlighted the potential importance of biomarkers in blood to assist with diagnosing AD.

Original languageEnglish
Article number63
Pages (from-to)1-20
Number of pages20
JournalJournal of Personalized Medicine
Issue number3
Publication statusPublished - Sept 2020


Dive into the research topics of 'Advantages and pitfalls in fluid biomarkers for diagnosis of Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this